 Artist: Bireli Lagrene: mp3 download Genre(s): Jazz Other Bireli Lagrene's discography:  To bi or not to bi Year: 2006 Tracks: 12  Gipsy Project Year: 2001 Tracks: 15  Standards Year: 2000 Tracks: 12  Blue Eyes Year: 1998 Tracks: 13  My Favorite Django Year: 1995 Tracks: 11  Acoustic Moments Year: 1991 Tracks: 10  Inferno Year: 1990 Tracks: 8  A Tribute to Django Reinhardt - 01-jun-85 - Disc2 Year: 1985 Tracks: 11  A Tribute to Django Reinhardt - 22-jun-84 - Disc1 Year: 1984 Tracks: 9  A tribute to Django Reinhardt Year: Tracks: 2 When Bireli Lagrene number one emerged in 1980 as a 13-year-old wHO sounded incisively like Django Reinhardt, he was considered a marvel. Born (like Reinhardt) to a gipsy menage, he had been playing guitar since he was four-spot. After a few age and several recordings, Lagrene advisedly got away from the Reinhardt influence, playacting high-powered rock-oriented optical merger and recording with Jaco Pastorius in 1986. He sounded more than original merely much less interesting during this geologic period. The guitarist has since returned to a quieter radiation diagram of jazz, playing difficult boP versions of standards with hints of his earlier interests in Reinhardt and nuclear fusion. Bireli Lagrene has recorded for Antilles, Jazzpoint, Blue Note, and Dreyfus. |
Wednesday 10 September 2008
Mp3 music: Bireli Lagrene
Thursday 21 August 2008
Geron Initiates Clinical Trial Of GRN163L In Combination With Paclitaxel And Bevacizumab In Patients With Breast Cancer
�Geron Corporation (Nasdaq: GERN) announced the enrollment of the first base patient in a clinical trial of its telomerase inhibitor dose, GRN163L, in locally repeated or metastatic breast cancer.
The main objective of the Phase I/II, dosage escalation written report is to determine the safety, maximum tolerated back breaker (MTD) and objective response rate of GRN163L when administered intravenously in combination with a paclitaxel/bevacizumab regime in this patient population.
"We ar excited to have enrolled the first patient in this study," said Kathy D. Miller, M.D., Associate Director for Clinical Research at the Indiana University Melvin and Bren Simon Cancer Center and lead investigator of the test. "We let anticipated the clinical rating of this drug in breast crab based on promising preclinical studies."
"This is an important milestone in the clinical development of our lead antitumour drug," said Fabio Benedetti, M.D., Geron's chief medical officer, oncology. "Extending the clinical testing of GRN163L to breast cancer reflects the potentially broad and important function of telomerase in fighting cancer."
The current study is the fifth clinical trial of GRN163L. Studies are ongoing at 14 other U.S. medical centers in patients with chronic lymphoproliferative diseases, multiple myeloma, non-small mobile phone lung malignant neoplastic disease, and other solid tumour malignancies administering GRN163L as either a single agent or in combination with conventional treatments. More info about these trials can be institute in the Patient Information section of Geron's site at hTTP://www.geron.com or on the NIH clinical trials register at hTTP://www.clinicaltrials.gov (search "GRN163L").
About Breast Cancer
Breast cancer is the most often diagnosed cancer the Crab in women, with an estimated incidence in the United States of more than clxxx,000 new cases and over 40,000 deaths this year. In addition, about 2,000 cases of chest cancer ar expected to occur in men, account statement for 1% of all new breast cancers.
A regimen of paclitaxel and bevacizumab is a current standard handling for metastatic breast malignant neoplastic disease. Paclitaxel is an anti-mitotic agent put-upon as a standard chemotherapy drug. Bevacizumab is a monoclonal antibody against vascular endothelial emergence factor (VEGF) used in combination with standard chemotherapy for the treatment of multiple metastatic cancers.
About Telomerase and GRN163L
Telomerase is a critical and potentially broadly applicable tumor target. The enzyme is expressed in a wide range of malignant tumors, and its activity is essential for the indefinite replicative mental ability of cancer cells that enables their malignant emergence. Telomerase is absent or expressed only transiently at low levels in nearly normal grownup tissues.
GRN163L is a short strand oligonucleotide that binds with very high affinity and specificity to the catalytic site of telomerase, resulting in competitive inhibition of enzyme activity. Proprietary manufacture chemistry and 5' lipoid chain were developed to improve the molecule's ability to penetrate cells and tissues.
GRN163L has demonstrated preclinical antitumor effects in a spacious range of hematological and solid tumour models, including breast cancer.
Geron is a biopharmaceutical company that is developing first-in-class therapeutic products for the treatment of malignant neoplastic disease and chronic degenerative diseases, including spinal anesthesia cord injury, heart failure and diabetes. The products are based on our core expertness in telomerase and human embryonic stem cells. For more information, visit hypertext transfer protocol://www.geron.com.
This news handout may stop forward-looking statements made pursuant to the "safe harbour" provisions of the Private Securities Litigation Reform Act of 1995. Investors ar cautioned that statements in this press release regarding potential applications of Geron's telomerase engineering science constitute forward-looking statements that involve risks and uncertainties, including, without limitation, risks inherent in the ontogeny and commercialisation of potency products, precariousness of clinical trial results or regulative approvals or clearances, motivation for future capital, dependance upon collaborators and criminal maintenance of our intellectual property rights. Actual results may differ materially from the results awaited in these forward-looking statements. Additional information on potential difference factors that could affect our results and early risks and uncertainties ar detailed from time to time in Geron's occasional reports, including the every quarter report on Form 10-Q for the quarter over June 30, 2008.
Geron Corporation
More info
The main objective of the Phase I/II, dosage escalation written report is to determine the safety, maximum tolerated back breaker (MTD) and objective response rate of GRN163L when administered intravenously in combination with a paclitaxel/bevacizumab regime in this patient population.
"We ar excited to have enrolled the first patient in this study," said Kathy D. Miller, M.D., Associate Director for Clinical Research at the Indiana University Melvin and Bren Simon Cancer Center and lead investigator of the test. "We let anticipated the clinical rating of this drug in breast crab based on promising preclinical studies."
"This is an important milestone in the clinical development of our lead antitumour drug," said Fabio Benedetti, M.D., Geron's chief medical officer, oncology. "Extending the clinical testing of GRN163L to breast cancer reflects the potentially broad and important function of telomerase in fighting cancer."
The current study is the fifth clinical trial of GRN163L. Studies are ongoing at 14 other U.S. medical centers in patients with chronic lymphoproliferative diseases, multiple myeloma, non-small mobile phone lung malignant neoplastic disease, and other solid tumour malignancies administering GRN163L as either a single agent or in combination with conventional treatments. More info about these trials can be institute in the Patient Information section of Geron's site at hTTP://www.geron.com or on the NIH clinical trials register at hTTP://www.clinicaltrials.gov (search "GRN163L").
About Breast Cancer
Breast cancer is the most often diagnosed cancer the Crab in women, with an estimated incidence in the United States of more than clxxx,000 new cases and over 40,000 deaths this year. In addition, about 2,000 cases of chest cancer ar expected to occur in men, account statement for 1% of all new breast cancers.
A regimen of paclitaxel and bevacizumab is a current standard handling for metastatic breast malignant neoplastic disease. Paclitaxel is an anti-mitotic agent put-upon as a standard chemotherapy drug. Bevacizumab is a monoclonal antibody against vascular endothelial emergence factor (VEGF) used in combination with standard chemotherapy for the treatment of multiple metastatic cancers.
About Telomerase and GRN163L
Telomerase is a critical and potentially broadly applicable tumor target. The enzyme is expressed in a wide range of malignant tumors, and its activity is essential for the indefinite replicative mental ability of cancer cells that enables their malignant emergence. Telomerase is absent or expressed only transiently at low levels in nearly normal grownup tissues.
GRN163L is a short strand oligonucleotide that binds with very high affinity and specificity to the catalytic site of telomerase, resulting in competitive inhibition of enzyme activity. Proprietary manufacture chemistry and 5' lipoid chain were developed to improve the molecule's ability to penetrate cells and tissues.
GRN163L has demonstrated preclinical antitumor effects in a spacious range of hematological and solid tumour models, including breast cancer.
Geron is a biopharmaceutical company that is developing first-in-class therapeutic products for the treatment of malignant neoplastic disease and chronic degenerative diseases, including spinal anesthesia cord injury, heart failure and diabetes. The products are based on our core expertness in telomerase and human embryonic stem cells. For more information, visit hypertext transfer protocol://www.geron.com.
This news handout may stop forward-looking statements made pursuant to the "safe harbour" provisions of the Private Securities Litigation Reform Act of 1995. Investors ar cautioned that statements in this press release regarding potential applications of Geron's telomerase engineering science constitute forward-looking statements that involve risks and uncertainties, including, without limitation, risks inherent in the ontogeny and commercialisation of potency products, precariousness of clinical trial results or regulative approvals or clearances, motivation for future capital, dependance upon collaborators and criminal maintenance of our intellectual property rights. Actual results may differ materially from the results awaited in these forward-looking statements. Additional information on potential difference factors that could affect our results and early risks and uncertainties ar detailed from time to time in Geron's occasional reports, including the every quarter report on Form 10-Q for the quarter over June 30, 2008.
Geron Corporation
More info
Tuesday 12 August 2008
Wednesday 6 August 2008
The Kraft
Artist: The Kraft
Genre(s):
Drum & Bass
Discography:
Feedback EP
Year: 2001
Tracks: 4
Blade (2000)
Year: 2000
Tracks: 2
Charge (CHRG002)
Year: 1998
Tracks: 2
Monday 23 June 2008
Tender Forever
Artist: Tender Forever
Genre(s):
Rock
Discography:
Wider
Year: 2007
Tracks: 12
The Soft And The Hardcore
Year: 2005
Tracks: 12
Melanie Valera was portion of a little girl group comprehend band in her hometown of Bordeaux, France, before landing in Portland, OR, and starting Tender Forever in 2005. On Soft and the Hardcore, which appeared later that year through K Records, Valera panax quinquefolius tender, highly personal songs around individuality, relationships, and pickings off your shirt, ensuant herself with simplistic acoustic guitar and laptop melodies. Similarities to Mirah and Anna Oxygen were acknowledged. Indulgent and the Hardcore was recorded at Dub Narcotic with help from Calvin Johnson and Khaela Maricich (aka the Blow); Tender Forever later toured the U.S. with Johnson.
Sheen Urges The Elderly To Get Active
Monday 16 June 2008
Hannah Montana Scoops Up Swift
Hannah Montana is getting a little bit (more) country.
Nashville ingenue Taylor Swift has filmed a cameo role in Hannah Montana: The Movie.
The 18-year-old Swift filmed the...
Sunday 8 June 2008
Znowhite
Artist: Znowhite
Genre(s):
Other
Discography:
Act Of God
Year: 1988
Tracks: 9
One of the several American alloy bands whose number 1 home photograph came by direction of the Alloy Massacre compilation series (in this case Vol. 3, which featured their 1983 song "Hellbent"), Chicago speed metal act Znowhite was formed in 1982 by guitar and drum-playing siblings Ian Tafoya (aka Greg Fulton) and Sparks Tafoya, their bass-playing cousin-german Nicky Tafoya, and, after some view, their manager's girlfriend, Nicole Lee, as lead isaac Merrit Singer. After a short time exploitation the more traditional spelling of Snowhite (a bring up chosen in irony since all but Lee were in fact African-Americans), the band fictitious the more distinctive "Z" spelling and got down to business sector with a copulate of releases through and through indie metallic element pronounce Enigma, namely 1984's All Hail to Thee EP and 1985's Kick 'Em When They're Down album.
Only these met with little success, Lee cease for a number of years (replaced by one Sue Sharp), and by the time she and Tafoya resurrected Znowhite with a new round department (bassist Alex Olvera and drummer Scott Schafer) and album (1988's Roadrunner-released Act of God), whatsoever sorting of momentum had been squandered. Following withal some other personnel department upheaval the succeeding year (including the reaching of isaac Merrit Singer Debbie Gunn and drummer John Slattery), Tafoya distinct to give up and begin fresh, with his real list and a new thrash circle called Cyclone Temple.
Adam Sandler raises hair in new movie "Zohan"
Subscribe to:
Posts (Atom)